Medicação de alto custo para portador de sofrimento psíquico: Um estudo preliminar dos custos

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorBarbosa, Guilherme Correa
dc.creatorMoreno, Vânia
dc.creatorJuliani, Carmen Maria Casquel Monti
dc.creatorSpiri, Wilza Carla
dc.creatorMolina Lima, Silvana Andrea
dc.date2014-05-27T11:22:23Z
dc.date2016-10-25T18:23:30Z
dc.date2014-05-27T11:22:23Z
dc.date2016-10-25T18:23:30Z
dc.date2007-01-01
dc.date.accessioned2017-04-06T01:23:32Z
dc.date.available2017-04-06T01:23:32Z
dc.identifierActa Scientiarum - Health Sciences, v. 29, n. 1, p. 19-23, 2007.
dc.identifier1679-9291
dc.identifierhttp://hdl.handle.net/11449/69491
dc.identifierhttp://acervodigital.unesp.br/handle/11449/69491
dc.identifier10.4025/actascihealthsci.v29i1.118
dc.identifier2-s2.0-55049109893.pdf
dc.identifier2-s2.0-55049109893
dc.identifierhttp://dx.doi.org/10.4025/actascihealthsci.v29i1.118
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/890727
dc.descriptionThe present work aims to raise the costs of high-cost drugs used to treat patients of Refractory Schizophrenia in ambulatory unit. The study was carried out in the Psychosocial Support Center, which treated 33 patients with these medications, during the period of June, 2005 to May, 2006. Data analysis disclosed that the mostly used drugs to treat the carriers of Refractory Schizophrenia were: clozapina and risperidona. It was observed that the treatment with olanzapina is more expensive than that with risperidona. The study concluded that the analysis of the consumption and costs of drugs of high cost is necessary to subside better management of the expenses and new investments in the service. Moreover, the necessity of more studies in the area was also identified to contribute with the control of costs.
dc.languagepor
dc.relationActa Scientiarum: Health Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAtypical antipsychotics
dc.subjectCosts
dc.subjectSchizophrenia
dc.subjectclozapine
dc.subjectneuroleptic agent
dc.subjectolanzapine
dc.subjectquetiapine
dc.subjectrisperidone
dc.subjectziprasidone
dc.subjectambulatory care
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcost control
dc.subjectcost effectiveness analysis
dc.subjectdrug cost
dc.subjectdrug use
dc.subjecthuman
dc.subjectmental health service
dc.subjectschizophrenia
dc.titleMedicação de alto custo para portador de sofrimento psíquico: Um estudo preliminar dos custos
dc.typeOtro


Este ítem pertenece a la siguiente institución